Advertisement

Immune Checkpoint Inhibitors in Sarcoma

  • Sandra P. D’AngeloEmail author
  • Ciara M. Kelly
Chapter

Abstract

Immunotherapy is now recognized as an effective therapeutic option for many cancer types. Checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have emerged as pivotal agents in the paradigm shift that we have witnessed in cancer management. The FDA has approved many of these agents to treat a variety of cancers including melanoma, lung cancer, renal and bladder cancer to name but a few. Research examining the role of immunotherapy in the management of sarcoma is in its infancy. To date, a limited number of early phase clinical trials have been performed in patients with advanced sarcoma. These studies focused on incorporating checkpoint inhibition as monotherapy or doublet therapy. Ongoing immunotherapy trials in sarcoma are investigating checkpoint inhibition in combination with small molecule therapies, chemotherapy, radiation therapy, or other immunotherapy agents targeting different aspects of the immune system. This chapter reviews the literature surrounding the safety and efficacy of checkpoint inhibition in treating sarcomas and explores novel immunotherapeutic strategies incorporating checkpoint inhibition that may be considered in sarcoma.

Keywords

Sarcoma Checkpoint inhibition CTLA-4 Blockade PD-1/PD-L1 blockade Combination immunotherapy 

References

  1. 1.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.CrossRefGoogle Scholar
  2. 2.
    Page DB, Yuan J, Wolchok JD. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy. 2010;2:367–79.CrossRefGoogle Scholar
  3. 3.
    Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76–9.CrossRefGoogle Scholar
  4. 4.
    Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science. 1993;262:905–7.CrossRefGoogle Scholar
  5. 5.
    Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1:793–801.CrossRefGoogle Scholar
  6. 6.
    Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science. 2006;313:1972–5.CrossRefGoogle Scholar
  7. 7.
    Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–53.CrossRefGoogle Scholar
  8. 8.
    Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–77.CrossRefGoogle Scholar
  9. 9.
    Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol. 2010;37:450–4.CrossRefGoogle Scholar
  10. 10.
    Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefGoogle Scholar
  11. 11.
    Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94.CrossRefGoogle Scholar
  12. 12.
    Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of Anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013;2013:168145.CrossRefGoogle Scholar
  13. 13.
    Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.CrossRefGoogle Scholar
  14. 14.
    Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140–5.CrossRefGoogle Scholar
  15. 15.
    Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887–95.CrossRefGoogle Scholar
  16. 16.
    Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.CrossRefGoogle Scholar
  17. 17.
    Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–29.CrossRefGoogle Scholar
  18. 18.
    Prasad V, Kaestner V, Mailankody S. Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncol. 2018;4:157–8.CrossRefGoogle Scholar
  19. 19.
    Ben-Ami E, Barysauskas CM, Solomon S, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer. 2017;123:3285–90.CrossRefGoogle Scholar
  20. 20.
    Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493–501.CrossRefGoogle Scholar
  21. 21.
    Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17.CrossRefGoogle Scholar
  22. 22.
    D’Angelo SP Mahoney MR, Van Tine BA, et al. A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401). American Society of Clinical Oncology Annual Meeting, Chicago, USA. 2017.CrossRefGoogle Scholar
  23. 23.
    Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31.CrossRefGoogle Scholar
  24. 24.
    Sharma A, Bode B, Studer G, et al. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clin Cancer Res. 2013;19:4843–53.CrossRefGoogle Scholar
  25. 25.
    Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69:2514–22.CrossRefGoogle Scholar
  26. 26.
    Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia. 2010;24:896–900.CrossRefGoogle Scholar
  27. 27.
    Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772–82.CrossRefGoogle Scholar
  28. 28.
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.CrossRefGoogle Scholar
  29. 29.
    Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.CrossRefGoogle Scholar
  30. 30.
    Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38.CrossRefGoogle Scholar
  31. 31.
    D’Angelo SP, Shoushtari AN, Keohan ML, et al. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib Study of dasatinib plus ipilimumab. Clin Cancer Res. 2017;23:2972–80.CrossRefGoogle Scholar
  32. 32.
    Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094–100.CrossRefGoogle Scholar
  33. 33.
    Trent JC, Wathen K, von Mehren M, et al. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2011;29(15_suppl):10006.CrossRefGoogle Scholar
  34. 34.
    van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.CrossRefGoogle Scholar
  35. 35.
    Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388:488–97.CrossRefGoogle Scholar
  36. 36.
    Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23:263–72.CrossRefGoogle Scholar
  37. 37.
    Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205–18.CrossRefGoogle Scholar
  38. 38.
    Breelyn A, Wilky EA. A phase II study of concurrent Axitinib and Pembrolizumab in subjects with advanced alveolar soft part sarcoma and other soft tissue sarcomas. Connective Tissue Oncology Society, Maui, Hawaii. 2017.Google Scholar
  39. 39.
    Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3:436–43.CrossRefGoogle Scholar
  40. 40.
    Ko HJ, Kim YJ, Kim YS, et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007;67:7477–86.CrossRefGoogle Scholar
  41. 41.
    Fridlender ZG, Sun J, Singhal S, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther. 2010;18:1947–59.CrossRefGoogle Scholar
  42. 42.
    Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713–21.CrossRefGoogle Scholar
  43. 43.
    Guo Z, Wang H, Meng F, Li J, Zhang S. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. J Transl Med. 2015;13:247.CrossRefGoogle Scholar
  44. 44.
    Barone A, Chi DC, Theoret MR, et al. FDA approval summary: trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen. Clin Cancer Res. 2017;23:7448–53.CrossRefGoogle Scholar
  45. 45.
    Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefGoogle Scholar
  46. 46.
    Herbst RS, Gordon M, Fine GD, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013;31:3000.Google Scholar
  47. 47.
    Larkin J, Minor D, D’Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in checkmate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36:383–90.CrossRefGoogle Scholar
  48. 48.
    Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.CrossRefGoogle Scholar
  49. 49.
    D’Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46:357–65.CrossRefGoogle Scholar
  50. 50.
    Raj SBM, Gonzales R, et al. Impact of PD-L1 expression on clinical outcomes in subtypes of sarcoma. Ann Oncol. 2014;25(suppl 4):iv498.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Memorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations